These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35506179)

  • 1. Type 2 diabetes medication and HbA1c levels in North Karelia Finland, 2013-2019.
    Wikström K; Lamidi ML; Rautiainen P; Tirkkonen H; Laatikainen T
    Diabet Med; 2022 Sep; 39(9):e14866. PubMed ID: 35506179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of co-payment level increase of antidiabetic medications on glycaemic control: an interrupted time-series study among Finnish patients with type 2 diabetes.
    Lavikainen P; Aarnio E; Jalkanen K; Tirkkonen H; Rautiainen P; Laatikainen T; Martikainen J
    BMC Health Serv Res; 2020 Nov; 20(1):1095. PubMed ID: 33246453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study.
    Manski-Nankervis JA; Thuraisingam S; Sluggett JK; Kilov G; Furler J; O'Neal D; Jenkins A
    BMC Fam Pract; 2019 Feb; 20(1):29. PubMed ID: 30777033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
    Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
    Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
    Fu AZ; Sheehan JJ
    Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis.
    Whyte MB; Hinton W; McGovern A; van Vlymen J; Ferreira F; Calderara S; Mount J; Munro N; de Lusignan S
    PLoS Med; 2019 Oct; 16(10):e1002942. PubMed ID: 31589609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
    Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
    Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
    BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study.
    Raebel MA; Ellis JL; Schroeder EB; Xu S; O'Connor PJ; Segal JB; Butler MG; Schmittdiel JA; Kirchner HL; Goodrich GK; Lawrence JM; Nichols GA; Newton KM; Pathak RD; Steiner JF
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):699-710. PubMed ID: 24639086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct trajectories of HbA
    Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
    Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities - a register-based retrospective cohort study in Finland.
    Nazu NA; Wikström K; Lamidi ML; Lindström J; Tirkkonen H; Rautiainen P; Laatikainen T
    BMC Prim Care; 2022 Nov; 23(1):278. PubMed ID: 36352358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database.
    Watson L; Das R; Farquhar R; Langerman H; Barnett AH
    Curr Med Res Opin; 2016 Sep; 32(9):1465-75. PubMed ID: 26907851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
    Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
    Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.